期刊文献+

利塞膦酸钠对糖皮质激素诱导的骨质疏松的疗效观察 被引量:4

Efficacy of Risedronate in the Treatment of Corticosteroid-induced Osteoporosis
原文传递
导出
摘要 目的研究利塞膦酸钠对长期服用糖皮质激素患者骨代谢的影响。方法采用随机、双盲、安慰剂对照研究,40例长期服用糖皮质激素患者分为治疗组和对照组,治疗组利塞膦酸钠给药5 mg.d-1,对照组等剂量给予安慰剂治疗。每位受试者在服药前及服药后12个月分别检测1次骨密度(BMD)、血生化指标及骨代谢标志物。结果与对照组相比,利塞膦酸钠能显著增加受试患者BMD,并显著降低血清骨钙素及尿I型胶原交联氨基端肽。结论利塞膦酸钠可防止糖皮质激素诱导的骨丢失,降低骨转换、改善骨密度,是治疗糖皮质激素诱导的骨质疏松的安全和有效的药物。 OBJECTIVE To study the bone metabolism in corticosteroids-treated patients with risedronate treatment. METHODS Forty ambulatory patients who took high-dose corticosteroids therapy, were randomly, double-blindly divided into two groups: treatment group (20 patients) were treated with risedronate sodium(5 mg.d-1) and control group(20 patients) were treated with placebo for 12 months. The efficacy of the treatment was evaluated by bone mineral density(BMD) measurements at spine and hip at the 12th month of the treatment and by the measurement of bone turnover marks. RESULTS After 12 months, in treatment group, BMD in the lumbar vertebrae and hip was significantly increased, and bone turnover marks ameliorated significantly compared with control group. CONCLUSION The risedoronate can increase BMD and ameliorate bone metabolism in patients with corticosteroids-induced osteoporosis.
出处 《中国现代应用药学》 CAS CSCD 北大核心 2011年第6期585-588,共4页 Chinese Journal of Modern Applied Pharmacy
关键词 利塞膦酸钠 糖皮质激素 骨质疏松 骨密度 risedoronate corticosteroid osteoporosis bone mineral density
  • 相关文献

参考文献1

二级参考文献5

  • 1Francis RM. Bisphosphonates in the treatment of osteoporosis [ J]. Curr Ther Res, 1997 ;58 : 656 - 678.
  • 2Heaney RP, Zizic TM, Fogelman I, et al. Risedronate reduces the risk of first vertebral fracture in osteoporetic women [ J ]. Osteoporos Int, 2002 ; 13 : 501 - 505.
  • 3Reginster JY, Minne HW, Sorensen O, et al. Randomized trial of effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis [ J ]. Osteoporos Int,2000 ; 11 : 83 - 91.
  • 4Taggart H, Bolognese MA, Lindsay R, et al. Upper gastrointestinal tract safety of risedronate : a pooled analysis of 9 clinical trials [ J ]. Mayo Clin Proc, 2002 ;77 : 262 - 270.
  • 5Frank LL, Richard HH, Alan BRT, et al. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women [ J ]. Gastroenterology, 2000 , 119:631 - 638.

共引文献4

同被引文献27

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部